# A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLC

> **NCT06812260** · PHASE2 · RECRUITING · sponsor: **Shanghai Henlius Biotech** · enrollment: 26 (estimated)

## Conditions studied

- SCLC, Extensive Stage

## Interventions

- **DRUG:** HLX10+chemo

## Key facts

- **NCT ID:** NCT06812260
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-24
- **Primary completion:** 2026-08-31
- **Final completion:** 2027-08-31
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2025-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06812260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06812260, "A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06812260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*